GLICK, B.; LAIN, E.; LIN, T.; ISRAEL, R. Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S30, 2019. DOI: 10.25251/skin.3.supp.30. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/757. Acesso em: 3 jul. 2024.